West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services Trading Up 1.0 %
WST opened at $340.98 on Friday. The stock has a market capitalization of $25.25 billion, a price-to-earnings ratio of 37.84, a PEG ratio of 1.37 and a beta of 1.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.13 and a quick ratio of 2.41. The business has a fifty day moving average price of $310.98 and a 200 day moving average price of $346.28. West Pharmaceutical Services has a 12 month low of $275.89 and a 12 month high of $475.35.
West Pharmaceutical Services (NYSE:WST - Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical instruments supplier reported $2.47 earnings per share for the quarter, topping analysts' consensus estimates of $2.19 by $0.28. The business had revenue of $771.30 million for the quarter, compared to analysts' expectations of $754.25 million. West Pharmaceutical Services had a net margin of 23.41% and a return on equity of 29.08%. The business's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.46 EPS. Sell-side analysts expect that West Pharmaceutical Services will post 9.1 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, StockNews.com downgraded West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research report on Thursday, April 28th.
Insider Activity at West Pharmaceutical Services
In other West Pharmaceutical Services news, insider Silji Abraham sold 5,374 shares of the company's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $343.93, for a total value of $1,848,279.82. Following the transaction, the insider now owns 3,201 shares of the company's stock, valued at $1,100,919.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.60% of the company's stock.